<div class="flex flex-col justify-start items-start self-stretch flex-grow-0 flex-shrink-0 gap-6"><div class="flex flex-col justify-start items-start self-stretch flex-grow-0 flex-shrink-0 gap-2"><div class="flex flex-col justify-start items-start self-stretch flex-grow-0 flex-shrink-0"><div class="flex justify-center items-center self-stretch flex-grow-0 flex-shrink-0 relative gap-2.5"><p class="flex-grow text-lg text-left text-[#191919]"><span class="flex-grow text-lg font-bold text-left text-[#191919]">References: 1. </span><span class="flex-grow text-lg text-left text-[#191919]">CHOLBAMÂ® (cholic acid) capsules. Prescribing Information. Mirum Pharmaceuticals, Inc. </span><span class="flex-grow text-lg font-bold text-left text-[#191919]">2. </span><span class="flex-grow text-lg text-left text-[#191919]">Elias ER, Orth LE, Li A, Xu L, Jones SM, Rizzo WB. Cholic acid increases plasma cholesterol in Smith-Lemli-Opitz syndrome: a pilot study. </span><span class="flex-grow text-lg italic text-left text-[#191919]">Mol Genet Metab Rep</span><span class="flex-grow text-lg text-left text-[#191919]">. 2023;38:101030. doi:10.1016/j.ymgmr.2023.101030 </span><span class="flex-grow text-lg font-bold text-left text-[#191919]">3.</span><span class="flex-grow text-lg text-left text-[#191919]"> Ferren EC, Hillman PR, Kritzer A, et al. Use of cholic acid in Smith-Lemli-Opitz Syndrome (SLOS): real-world patient outcomes. Poster presented at: 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting; March 18-22, 2025; Los Angeles, CA.</span></p></div></div></div></div>